Humanetics Corporation
Excelsior, MN
- UEI
- MSRQYLLQLYQ5
- CAGE
- 4B2E0
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 261 School Ave #210, Excelsior, MN 55331, USA
- Website
- humaneticscorp.com
- Founded
- 1988
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | -$7 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | HU00012420053 | $204,274 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Emergent Biosolutions Canada Inc. | Winnipeg, MB | 325412 Pharmaceutical Preparation Manufacturing |
| Bolder Biotechnology Inc. | Louisville, CO | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Orpro Therapeutics Inc. | San Diego, CA | — |
| Soligenix, Inc. | Princeton, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bavarian Nordic A / S | Hellerup | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Humanetics Corp is a for-profit biopharmaceutical company that develops medical countermeasures to treat the effects of radiation exposure, lung disease, and other indications.
Through federal grants, Humanetics Corp has conducted research and development of therapeutic candidates including BIO 300 and BIO 301. These grants were awarded by agencies such as the National Institutes of Health, Department of Defense, and Department of the Army to support programs in areas like cardiovascular disease, chemical and biological defense, and military medical research and development. Specific activities funded include preclinical efficacy studies, clinical trials, formulation development, and regulatory planning for radiation mitigation treatments and COVID-19-associated lung therapies.
Humanetics Corp also holds an Other Transaction IDV from the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to develop an oral formulation of BIO 300. This $19.5 million IDV aims to produce BIO 300 oral tablets as an alternate delivery mechanism for the therapeutic. Work will involve necessary preclinical and clinical studies to achieve regulatory approval. Performance will occur at Humanetics facilities and partner sites. Task orders will fund discrete development projects over the IDV's period of performance.
Quick answers
Is Humanetics Corporation registered in SAM.gov?
Yes. Humanetics Corporation's SAM.gov registration is active through August 3, 2027.
What is Humanetics Corporation's most recent federal award?
Humanetics Corporation's most recent federal grant award is Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis (R43HL167432), from National Heart Lung and Blood Institute (NIH), on September 1, 2023.
On GovTribe
See Humanetics Corporation's full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors